Biotech stocks can be some of the hottest, best-performing stocks on the market. But they're also some of the riskiest.
That's why comparing bluebird bio (NASDAQ: BLUE), a biotech stock with enormous potential, against the more established healthcare giant Gilead Sciences (NASDAQ: GILD) is not as easy a decision as it may seem, whether you're a growth investor or not. Let's take a closer look at the two stocks to see which one is the better buy, and under what circumstances.
Although its market cap is already $5 billion, Bluebird has the potential to become much bigger. The key to all of that growth: Zynteglo. The drug treats people with transfusion-dependent thalassemia (TDT), a rare genetic blood disorder that requires blood transfusions.